Progressive myoclonic epilepsy arising in the context of myoclonic epilepsy with ragged red fibers (MERRF) requires a treatment approach that accounts for the underlying mitochondrial syndrome. Drug selection in this population is shaped by specific constraints that do not apply in other forms of myoclonic epilepsy.
MERRF is a multisystem disorder characterized by myoclonus and other seizure types, ataxia, weakness, and dementia. Progressive myoclonic epilepsy in this setting occurs as part of a broader mitochondrial disease, which directly influences which antiepileptic agents are appropriate and which must be avoided.
Management centers on symptomatic antiepileptic drug therapy for seizure control. A critical constraint in MERRF is the mitochondrial toxicity profile of certain antiepileptic agents — some commonly used drugs carry significant mitochondrion-toxic effects and must be avoided in this population. The complete drug selection guidance, including which agents are preferred and the full sequencing, is detailed in the structured protocol.
Reduction or elimination of seizures, without severe side effects that would compromise quality of life.